MNPR
Monopar Therapeutics Inc
NASDAQ: MNPR · HEALTHCARE · BIOTECHNOLOGY
$73.39
+2.16% today
Updated 2026-10-28
Market cap
$474.21M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.20
Dividend yield
—
52W range
$50 – $125
Volume
0.2M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C9.0
Quality
A+3.0
Profitability
D5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
28.5
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$129.92
+77.03%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 28.51 — safe zone
+ Debt/equity 0.00x — low leverage
Risks
- Thin margins at 0.00%
- Negative free cash flow $-3.25B
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-10.49M | $-8.40M | $-15.59M | $-13.72M | $-5.31M |
| EPS | — | — | — | — | $-2.20 |
| Free cash flow | $-7.23M | $-7.86M | $-6.40M | $-12.20M | $-3.25B |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-09-30 | VU, QUAN ANH | Sale | 614 | — |
| 2026-09-30 | VU, QUAN ANH | Buy | 614 | — |
| 2026-09-30 | VU, QUAN ANH | Sale | 180 | $79.67 |
Peer comparison
Smart narrative
Monopar Therapeutics Inc trades at $73.39. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 28.51, it sits in the safe zone.
Frequently asked questions
What is Monopar Therapeutics Inc's stock price?
Monopar Therapeutics Inc (MNPR) trades at $73.39.
Is Monopar Therapeutics Inc overvalued?
Monopar Therapeutics Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Monopar Therapeutics Inc (MNPR)?
The 12-month analyst consensus target is $129.92, about 77.0% above the current $73.39. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Monopar Therapeutics Inc's Altman Z-Score is 28.51, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-13.64%
Beta1.51
50D MA$95.58
200D MA$77.09
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.2M
Performance
1 week+1.12%
1 month-8.26%
3 months-35.99%
YTD+12.39%
1 year-12.79%
3 years—
5 years—